Journal
JOURNAL OF PSYCHIATRIC RESEARCH
Volume 44, Issue 9, Pages 561-565Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jpsychires.2009.11.020
Keywords
Bipolar disorder; NT-3; Biological marker; Depression; Mania; Mood stabilizers
Categories
Funding
- Stanley Medical Research Institute
- NARSAD
- INCT for Translational Medicine
- CNPq
- CAPES
- FIPE-HCPA
- SMRI
- Lilly
- AstraZeneca
- Janssen
Ask authors/readers for more resources
Bipolar disorder (BD) has been increasingly associated with abnormalities in neuroplasticity. Previous studies demonstrated that neurotrophin-3 (NT-3) plays a role in the pathophysiology of mood disorders. The influence of medication in these studies has been considered a limitation. Thus, studies with drug-free vs. medicated patients are necessary to evaluate the role of medication in serum NT-3 levels. About 10 manic and 10 depressive drug-free, and 10 manic and 10 depressive medicated patients with BD type I were matched with 20 controls for sex and age. Patients were assessed using SCID-I, YMRS and HORS. Serum NT-3 levels in drug-free and medicated patients is increased when compared with controls (2.51 +/- 0.59, 2.56 +/- 0.44 and 1.97 +/- 0.33, respectively, p < 0.001 for drug-free/medicated vs. control). Serum NT-3 levels do not differ between medicated and drug-free patients. When analyzing patients according to mood states, serum NT-3 levels are increased in both manic and depressive episodes, as compared with controls (2.47 +/- 0.43, 2.60 +/- 0.59 and 1.97 +/- 0.33, respectively, p < 0.001 for manic/depressive patients vs. controls). There is no difference in serum BDNF between manic and depressive patients. Results suggest that increased serum NT-3 levels in BD are likely to be associated with the pathophysiology of manic and depressive symptoms. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available